The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study-Reference-Cited by-同舟云学术

The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study

Published:2024-02-29 Issue:2 Volume:167 Page:305-313
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Yu Meimei,Ge Ying,Wang Zixuan,Zhang Yang,Hou Xinyi,Chen Hongyan,Chen Xuzhu,Ji Nan,Li Xin,Shen Huicong

Funder

National Natural Science Foundation of China

Collaborative innovative major special project supported by Beijing Municipal Science & Technology Commission

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11060-024-04609-2.pdf

Reference44 articles.

1. Miller JJ, Gonzalez Castro LN, McBrayer S et al (2022) Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol 25:4. https://doi.org/10.1093/neuonc/noac207

2. Cahill DP (2021) Extent of resection of glioblastoma: a critical evaluation in the molecular era. Neurosurg Clin N Am 32:23–29. https://doi.org/10.1016/j.nec.2020.09.006

3. Suh CH, Kim HS, Jung SC et al (2018) 2-hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data. Neuro Oncol 20:1573–1583. https://doi.org/10.1093/neuonc/noy113

4. Jain R, Johnson DR, Patel SH et al (2020) “Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas. Neuro Oncol 22:936–943. https://doi.org/10.1093/neuonc/noaa041

5. Cindil E, Sendur HN, Cerit MN et al (2022) Prediction of IDH mutation status in high-grade gliomas using DWI and high T1-weight DSC-MRI. Acad Radiol 29(Suppl 3):S52–S62. https://doi.org/10.1016/j.acra.2021.02.002